Company Encyclopedia
View More
name
XPH
300147.SZ
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sarsae, juice soda, soymilk, coconut juice, and fruit enzyme; and antiviral oral liquids under the Xiangxue brand name. It also provides medical devices, which includes disposable stereoscopic fixation system for brain; medical orthopedic and cosmetic adhesives; medical tumor serosa sealing adhesives; medical anastomotic adhesives; medical aural and encephalic adhesives; medical obturation adhesives; medical adhesives; and endoscopic trocar.
3.157 T
300147.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
PharmaceuticalsIndustry
Industry Ranking223/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-83.57%E
    • Profit Margin-68.16%E
    • Gross Margin46.22%B
  • Growth ScoreE
    • Revenue YoY-30.11%E
    • Net Profit YoY-117.64%E
    • Total Assets YoY-8.56%E
    • Net Assets YoY-48.09%E
  • Cash ScoreE
    • Cash Flow Margin-146.71%D
    • OCF YoY-30.11%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreE
    • Gearing Ratio85.08%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XPH: Xu Li resigned as the secretary of the board, Xiang Jin took over

    On September 30th, ST XPH announced that the company's director and board secretary Xu Li applied to resign from the position of board secretary for personal reasons, with the resignation taking effect from the date it is delivered to the board of directors. After resigning from the above position, Xu Li will still serve as a director of the company. The 30th meeting of the 9th board of directors approved the proposal on the appointment of the board secretary, agreeing to appoint Xiang Jin as the board secretary of the company, with a term starting from the date of approval by this board meeting until the end of the 9th board's term

    Zhitong·
    SZ
    300147
    +0.64%
    Zhitong·
    SZ
    300147
    +0.64%

    XPH released its performance for the first half of the year, with a net loss attributable to the parent company of 234 million yuan, an increase of 72.96%

    According to the Zhitong Finance APP, XPH released its semi-annual report for 2025, showing an operating income of 818 million yuan, a year-on-year decrease of 25.40%. The net loss attributable to shareholders of the listed company was 234 million yuan, a year-on-year increase of 72.96%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 207 million yuan, a year-on-year increase of 91.43%. The basic loss per share was 0.35 yuan

    Zhitong·
    SZ
    300147
    +0.64%
    Zhitong·
    SZ
    300147
    +0.64%

    China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit first

    China Galaxy Securities released a research report stating that cell gene therapy (CGT) has entered a period of realization of results, becoming the most promising development direction in the biopharmaceutical field. CGT has a high outsourcing ratio and high market concentration, with CXO expected to benefit first. Focus on companies with high pipeline maturity and good clinical trial data. Products such as CAR-T and TCR-T are being launched one after another, and the industry's prosperity continues to improve, with active investment and financing

    Zhitong·
    SZ
    300147
    +0.64%
    SZ
    000597
    -0.70%
    Zhitong·
    SZ
    300147
    +0.64%
    SZ
    000597
    -0.70%

    XPH: TAEST1901 injection has received approval for clinical trials

    The subsidiary of XPH, Xiangxue Life Sciences, has received approval from the National Medical Products Administration for the clinical trial application of the new drug TAEST1901 injection. This drug is suitable for the treatment of advanced gastric cancer with the genotype HLA-A*02:01 and positive expression of the tumor antigen AFP

    Zhitong·
    SZ
    300147
    +0.64%
    Zhitong·
    SZ
    300147
    +0.64%

    XPH: Guangzhou Intermediate People's Court agrees to the company's pre-restructuring and appoints a temporary administrator

    XPH announced that the Guangzhou Intermediate People's Court has agreed to a 3-month pre-restructuring and has appointed King & Wood Mallesons (Guangzhou) and Guangdong Dongfang Kunlun Law Firm as temporary administrators. This decision does not represent the formal acceptance of Jinglong Construction's restructuring application by the Guangzhou Intermediate People's Court, and there remains uncertainty regarding the initiation of the restructuring process

    Zhitong·
    SZ
    300147
    +0.64%
    Zhitong·
    SZ
    300147
    +0.64%
    © 2025 Longbridge｜Disclaimer